Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 3/20 | 0.41 |
| ▸ | MITF | O75030 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036087 | 0.84 | ALDH1A1 (0.51) | KMT2AMEN1POLBALDH1A1HSD17B10 | |
| SCHEMBL1773565 | 0.84 | KMT2A (0.60) | KMT2AMEN1POLBALDH1A1HSD17B10 | |
| SCHEMBL10036086 | 0.77 | MEN1 (0.72) | KMT2AMEN1POLBALDH1A1HSD17B10 | |
| SCHEMBL11878882 | 0.75 | KMT2A (0.48) | KMT2AMEN1POLBALDH1A1HSD17B10 | |
| SCHEMBL11878875 | 0.75 | KMT2A (0.48) | KMT2AMEN1POLBALDH1A1HSD17B10 | |
| SCHEMBL14273144 | 0.72 | KMT2A (0.60) | KMT2AMEN1POLBALDH1A1HSD17B10 | |
| SCHEMBL9054686 | 0.68 | MEN1 (0.60) | KMT2AMEN1POLBALDH1A1HSD17B10 | |
| SCHEMBL9054683 | 0.68 | MEN1 (0.60) | KMT2AMEN1POLBALDH1A1HSD17B10 | |
| SCHEMBL11319531 | 0.67 | KMT2A (0.57) | KMT2AMEN1POLBALDH1A1HSD17B10 | |
| SCHEMBL11319535 | 0.67 | KMT2A (0.57) | KMT2AMEN1POLBALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035187-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035187-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035187-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | SNCA, PSEN1, CDR2 | KMT2A 2624/4885MEN1 2218/4885POLB 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.